After examining data from large trials of autoimmune-disease medications called Interleukin-17 (IL-17) inhibitors, researchers at the Perelman School of Medicine at the University of Pennsylvania found individuals who took these treatments were about 30 to 60 percent more likely to develop symptoms associated with respiratory-tract infections. The findings could signify that IL-17 inhibitors may influence susceptibility to different viral and other types of respiratory infections.
Since the novel coronavirus is a type of viral respiratory infection, the results also encourage further investigation into a potential relationship between IL-17 inhibitors and COVID-19. The study was published recently in the Journal of the American Academy of Dermatology.
Researchers Suggest Increased Risk of Respiratory-Tract Infections in People on Certain Psoriasis Treatment
I do not know if it’s just me or if perhaps everyone else experiencing issues with your website.
It appears as though some of the text within your content are running off
the screen. Can somebody else please comment and let me know if this
is happening to them too? This could be a problem with my internet browser because I’ve
had this happen previously. Many thanks